Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards
Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this independent awards program highlights the most innovative companies, services, and products in the highly competitive baby care industry.Camilia...
2025-06-26 2:00 PM EDT | Boiron USA
Canadian Institute of Actuaries Announces Alicia Rollo as New Executive Director
Ottawa, Ontario--(Newsfile Corp. - June 26, 2025) - As the Canadian Institute of Actuaries (CIA) looks to the future, it welcomes new leadership, celebrates a legacy of service and shares key milestones in its continued advancement of the actuarial profession in Canada.Alicia Rollo appointed Executive Director, effective July 1, 2025The...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-26 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
L'Institut canadien des actuaires annonce la nomination d'Alicia Rollo au poste de directrice générale
Ottawa, Ontario--(Newsfile Corp. - 26 juin 2025) - Se tournant vers l'avenir, l'Institut canadien des actuaires accueille une nouvelle dirigeante, célèbre un héritage de service et partage des jalons importants de la progression soutenue de la profession actuarielle au Canada.Nomination d'Alicia Rollo au poste de directrice générale à compter du...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-26 12:00 PM EDT | Canadian Institute of Actuaries / FR: Institut canadien des actuaires
Liviniti Achieves HITRUST i1 Certification for Industry-Leading Security Practices
Certification demonstrates Liviniti's strong commitment to data security and risk managementNatchitoches, Louisiana--(Newsfile Corp. - June 26, 2025) - Liviniti, a national leader in PBM transparency and prescription drug savings, today announced it has achieved 2025 certified HITRUST status for information security. Platforms with HITRUST certification include the Liviniti client portal,...
2025-06-26 9:08 AM EDT | Liviniti
Hemostemix Announces Lead Order of $1,500,000 and the Full Repayment of $2,500,000 Convertible Debenture
Calgary, Alberta--(Newsfile Corp. - June 26, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces its Chairman, Peter Lacey, has provided the Company with a lead order for a non brokered private placement in the amount of $1,500,000 for Units at $0.10. Each Unit...
Biotechnology, Pharmaceuticals, Health
2025-06-26 9:00 AM EDT | Hemostemix Inc.
Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States
Fiscal year 2025 revenue of $108.3 million, record net income of $2.2 million, operating income of $8.2 million, and record Adjusted EBITDA* of $20.2 millionUS commercial launch of GRAFAPEX™ executed in February 2025, following swiftly on the FDA's approval in January 2025, with initial indicators supporting Medexus's confidence in the...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 6:15 PM EDT | Medexus Pharmaceuticals Inc.
Unbuzzd Launches $5 Million Reg D Capital Raise to Fund Growth and Path to Possible Initial Public Offering
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Unbuzzd Wellness Inc. (the "Company" or "Unbuzzd"), the company behind unbuzzdTM – the scientifically-proven and game-changing beverage that accelerates alcohol metabolism, restores mental clarity and reduces hangover symptoms - is pleased to announce that it has engaged MZ Digital, a global...
2025-06-25 8:30 AM EDT | Unbuzzd Wellness Inc.
InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has entered into definitive agreements with a single institutional...
Biotechnology, Pharmaceuticals
2025-06-25 8:00 AM EDT | InMed Pharmaceuticals
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort
-Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer....
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-25 7:45 AM EDT | Phio Pharmaceuticals Corp.
PreveCeutical Announces Date for Annual General and Special Meeting
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has scheduled its annual general and special meeting for August 15, 2025, at which the shareholders (the "PreveCeutical Shareholders") of the Company will be...
Biotechnology, Pharmaceuticals, Health
2025-06-25 7:00 AM EDT | PreveCeutical Medical Inc.
SOL Global Announces Board Changes and Strategic Focus on Crypto Innovation
Toronto, Ontario--(Newsfile Corp. - June 24, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional Solana investments, today announces changes to its Board of Directors as part of a broader strategic shift toward digital...
Healthcare and Hospitals, Pharmaceuticals
2025-06-24 8:00 AM EDT | SOL Global Investments Corp.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
Marlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-24 7:45 AM EDT | Phio Pharmaceuticals Corp.
InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study
Demonstrates statistically significant reduction of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/GroSignificantly reduces levels of inflammasome marker, NLRP3, a key contributor to neurodegenerationReduces key pro-inflammatory markers, independent of amyloid beta or tau pathologyVancouver, British Columbia--(Newsfile Corp. - June 24, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or t
Biotechnology, Pharmaceuticals
2025-06-24 7:00 AM EDT | InMed Pharmaceuticals
Beyond Medical Technologies Closes Second Tranche of Convertible Note Financing
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT) (FSE: 7FM) (OTC Pink: DOCKF) ("Beyond Medical" or the "Company") is pleased to announce the closing of the second tranche of its previously announced non-brokered private placement (the "Financing") for aggregate gross proceeds of CAD...
Technology, Pharmaceuticals, Health
2025-06-23 10:06 AM EDT | Beyond Medical Technologies Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Fiscal Year 2025 Financial Results on July 1, 2025
Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that it would release its 2025 year-end financial results on Monday, June 30, 2025. Elite's management will host a live conference...
Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-23 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Psyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025
Denver, Colorado--(Newsfile Corp. - June 18, 2025) - Psyence Biomedical Ltd. (NASDAQ: PBM) ("Psyence BioMed" or the "Company") today announced that Psychedelic Science 2025 ("PS2025") - the world's largest international gathering focused on psychedelic research, biopharma, medicine, policy, and culture, hosted by the Multidisciplinary Associ
Biotechnology, Pharmaceuticals, Health, Psychedelics
2025-06-18 8:30 AM EDT | Psyence Biomedical Ltd.
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, British Columbia--(Newsfile Corp. - June 18, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye, a current member of NervGen's Board of Directors...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-18 7:30 AM EDT | NervGen Pharma Corp.
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 17, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, June 26, 2025 to discuss Medexus's results for its fourth fiscal quarter and fiscal year ended March 31, 2025. Medexus...
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-06-17 5:00 PM EDT | Medexus Pharmaceuticals Inc.
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to...
Biotechnology, Pharmaceuticals, Health
2025-06-17 8:41 AM EDT | Hemostemix Inc.
SOL Global Announces Proposed Debt Settlement Transaction and Proposed Warrant Repricing
Toronto, Ontario--(Newsfile Corp. - June 17, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), one of the first publicly traded companies focused on institutional Solana investments, is pleased to announce that it expects to settle outstanding indebtedness totalling approximately $6,630,528 with a number...
Healthcare and Hospitals, Pharmaceuticals
2025-06-17 8:37 AM EDT | SOL Global Investments Corp.